Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 693–694 | Cite as

Spontaneous remission of methotrexateassociated lymphoproliferative disorder with Epstein-Barr virus type II latency

  • Yasushi MatsuzakiEmail author
  • Satoko Minakawa
  • Chihiro Sagara
  • Noriko Takiyoshi
  • Hajime Nakano
  • Daisuke Sawamura
Article
  • 2 Downloads

References

  1. 1.
    Liu X, Tang J, Wang M, Ma Q, Wang Y. Visual detection and evaluation of latent and lytic gene expression during Epstein–Barr virus infection using one–step reverse transcription loop–mediated isothermal amplification. Int J Mol Sci 2013; 14: 23922–40.CrossRefGoogle Scholar
  2. 2.
    Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991; 18: 1741–3.Google Scholar
  3. 3.
    Gaulard P, Swerdlow SH, Harris L, Jaffe ES, Sundstrom C. Other iatrogenic immunodeficiency–associated lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Swerdlow SH, Campo E, Harris NL, et al. Lyon: IARC Press, 2008: 350–1.Google Scholar
  4. 4.
    Mariette X, Cazals–Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3–year prospective study in France. Blood 2002; 99: 3909–15.CrossRefGoogle Scholar
  5. 5.
    Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007; 34: 322–31.Google Scholar
  6. 6.
    Kojima M, Itoh H, Hirabayashi K, et al. Methtrexate–associated lymphoproliferative disorders. a clinicopathological study of 13 Japanese cases. Pathol Res Pract 2006; 202: 679–85.CrossRefGoogle Scholar
  7. 7.
    Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 2013; 91: 20–8.CrossRefGoogle Scholar
  8. 8.
    Terroso G, Aleixo J, Bernardes M, Mariz E, Fonseca E, Costa L. Nasal type extranodal NK/T cell lymphoma diagnosed in a patient with rheumatoid arthritis under methotrexate. Acta Reumatol Port 2014; 39: 77–81.Google Scholar
  9. 9.
    Kondo S, Tanimoto K, Yamada K, et al. Mature T/NK–cell lymphoproliferative disease and Epstein–Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch 2013; 462: 399–407.CrossRefGoogle Scholar
  10. 10.
    Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate–associated lymphoproliferative disorders. J Rheumatol 2014; 41: 293–9.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Yasushi Matsuzaki
    • 1
    Email author
  • Satoko Minakawa
    • 1
  • Chihiro Sagara
    • 1
  • Noriko Takiyoshi
    • 1
  • Hajime Nakano
    • 1
  • Daisuke Sawamura
    • 1
  1. 1.Department of DermatologyHirosaki University Graduate School of MedicineHirosakiJapan

Personalised recommendations